Belite Bio, Inc. filings document foreign-issuer disclosures for a clinical-stage biopharmaceutical company developing tinlarebant for degenerative retinal diseases. Form 6-K reports furnish press releases on clinical-trial progress, FDA-related regulatory updates, financial results, annual-report availability, material agreements, shareholder matters, and capital-structure activity involving American Depositary Shares.
The company's Form 20-F reporting framework covers audited consolidated financial statements and public-company disclosure for BLTE as a foreign private issuer. Its filing record centers on STGD1, geographic atrophy in advanced dry AMD, tinlarebant development, financing activity, governance matters, and the incorporation of furnished reports into effective Securities Act registration statements.
Belite Bio chief scientific officer Nathan L. Mata reported open‑market sales of 1,000 American depositary shares (ADS) of the company. The transactions occurred on April 24 and were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 10, 2025.
The ADS were sold in multiple trades at prices including $162.53 and various weighted average prices in the high‑$150s to low‑$160s. Following these sales, Mata directly owns 8,666 ADS, each representing one ordinary share of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of the company on April 23, 2026. The sales were open-market transactions at prices ranging from about $164 to $170 per ADS and were executed under a Rule 10b5-1 trading plan adopted on 12/10/2025.
BELITE BIO, INC director and CEO Yu-Hsin Lin reported a compensation-related share vesting. On 04/21/2026, 10,000 ordinary shares were delivered upon vesting of restricted stock units granted on September 15, 2025 after specified performance criteria were met.
Following this non-market transaction, Lin directly holds 182,949 ordinary shares. The event reflects equity-based compensation vesting rather than an open-market purchase or sale.
Belite Bio’s Chief Medical Officer, Hendrik Peter Scholl, reported the vesting of a performance-based stock option held indirectly through Bioptima Ltd. The option covers 10,000 ordinary shares at an exercise price of $77.40 per share.
The option was originally granted on October 7, 2025 and vested on April 21, 2026 after specified performance criteria were met. Following this vesting event, 10,000 stock option rights remain outstanding under this grant, with an expiration date of October 6, 2035. This filing reflects a compensation-related milestone rather than an open-market share purchase or sale.
Belite Bio chief scientific officer Nathan L. Mata sold 1,000 American depositary shares of the company in open-market transactions. The Form 4 shows nine sales of Belite Bio ADS on April 22, 2026, at weighted average prices ranging from about $165.64 to $173.16. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Each ADS represents one ordinary share of Belite Bio.
Belite Bio, Inc. director and Chief Financial Officer Hao-Yuan Chuang reported a compensation-related share change. On April 21, 2026, restricted stock units granted on September 15, 2025 vested upon meeting performance criteria, delivering 10,000 ordinary shares at no stated price.
Following this RSU vesting, Chuang directly holds 205,264 ordinary shares of Belite Bio. The filing reflects an internal equity award vesting rather than an open-market purchase or sale.
Belite Bio Chief Scientific Officer Nathan L. Mata reported open‑market sales of a total of 1,000 American depositary shares on April 21, 2026 at prices within ranges from $163.26 to $167.94. Each ADS represents one ordinary share of the company.
The transactions were executed under a pre‑arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Following these sales, Mata holds 12,602 American depositary shares directly.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares (ADS) of BELITE BIO, INC in open-market transactions. The sales took place on April 20, 2026 at prices generally between about $162 and $168 per ADS. Each ADS represents one ordinary share of the company. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Belite Bio has begun a rolling submission of a New Drug Application to the U.S. FDA for tinlarebant, an oral therapy for Stargardt disease type 1, a rare inherited retinal disorder linked to ABCA4 mutations. Tinlarebant has Breakthrough Therapy, Fast Track, Rare Pediatric Disease, Orphan Drug, and Sakigake designations across major regions.
The company plans to complete the NDA rolling submission in the second quarter of 2026, supported by data including results from the Phase 3 DRAGON trial in adolescent patients. Tinlarebant is also in a Phase 2/3 STGD1 trial and a Phase 3 trial for geographic atrophy in advanced dry AMD.
Belite Bio, Inc. Chief Scientific Officer Nathan L. Mata sold a total of 1,000 American depositary shares in open-market transactions. The sales took place on April 17, 2026 at prices generally ranging from about $158 to $163 per share.
Each American depositary share represents one ordinary share of Belite Bio. The filing states that these sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily.